New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 22, 2014
07:05 EDTSLXP, PGNXSalix, Progenics announce RELISTOR EMA submission accepted
Salix (SLXP) and Progenics (PGNX) announced that the submission to the European Medicines Agency of RELISTOR has been accepted for review. If approved, this will add to the current marketing authorization in the European Union, which allows for the use of RELISTOR in advanced illness patients. The marketing of RELISTOR for the treatment of OIC in advanced illness patients was approved in the European Union in 2008, and is currently approved in more than 50 countries. If approved, it is anticipated that RELISTOR will be immediately available to this newly expanded population of patients in the EU using opioids to control chronic pain.
News For SLXP;PGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
18:18 EDTSLXPGlenview Capital acquires stake in Actavis, Bloomberg reports
Subscribe for More Information
October 21, 2014
07:07 EDTSLXPSalix to present results of TARGET 3 study with Rifaximin 550mg for IBS
Subscribe for More Information
October 20, 2014
08:19 EDTPGNXProgenics presents data from Phase 2 trial of 1404 PSMA imaging agent
Progenics Pharmaceuticals announced that data from a Phase 2 trial of its PSMA imaging agent candidate, 1404, have been presented at the 27th Annual European Association of Nuclear Medicine Congress being held in Gothenburg, Sweden. 1404 is a targeted small molecule designed to "visualize" prostate cancer by targeting prostate specific membrane antigen. "The Phase 2 data are quite impressive and demonstrate how SPECT/CT with 1404 may provide a more accurate assessment of the presence, location and extent of prostate cancer," said Dr. Dabasi. Gabriella Dabasi, Ph.D. presented, "1404 may provide prognostic information for both primary and metastatic disease in a single procedure, which could greatly enhance the clinical decision-making process. There is a strong rationale for continued development of this promising molecular imaging agent." In the Phase 2 trial, SPECT/CT imaging with 1404 showed 94% sensitivity in detecting and imaging cancer in the prostate gland of high-risk patients prior to prostatectomy. In addition, 1404 was more sensitive than MRI in detecting primary prostate cancer and was a good predictor of lymph node involvement at prostatectomy. SPECT/CT imaging with 1404 identified 14 more patients with suspicious lymph node sites than MRI. Uptake of 1404 in the lobes of the prostate gland showed a highly significant correlation with Gleason score. The data also showed uptake of 1404 in the primary tumor was significantly lower in treated patient, corresponding to a decrease in PSA over time observed in these treated patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use